Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3

Vladimir Bobkov, Marta Arimont, Aurélien Zarca, Timo W.M. De Groof, Bas van der Woning, Hans de Haard, Martine J. Smit

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Dysregulation of the chemokine system is implicated in a number of autoimmune and inflammatory diseases, as well as cancer. Modulation of chemokine receptor function is a very promising approach for therapeutic intervention. Despite interest from academic groups and pharmaceutical companies, there are currently few approved medicines targeting chemokine receptors. Monoclonal antibodies (mAbs) and antibody-based molecules have been successfully applied in the clinical therapy of cancer and represent a potential new class of therapeutics targeting chemokine receptors belonging to the class of G protein-coupled receptors (GPCRs). Besides conventional mAbs, single-domain antibodies and antibody scaffolds are also gaining attention as promising therapeutics. In this review, we provide an extensive overview of mAbs, single-domain antibodies, and other antibody fragments targeting CXCR4 and ACKR3, formerly referred to as CXCR7. We discuss their unique properties and advantages over small-molecule compounds, and also refer to the molecules in preclinical and clinical development. We focus on single-domain antibodies and scaffolds and their utilization in GPCR research. Additionally, structural analysis of antibody binding to CXCR4 is discussed. SIGNIFICANCE STATEMENT: Modulating the function of GPCRs, and particularly chemokine receptors, draws high interest. A comprehensive review is provided for monoclonal antibodies, antibody fragments, and variants directed at CXCR4 and ACKR3. Their advantageous functional properties, versatile applications as research tools, and use in the clinic are discussed.

Original languageEnglish
Pages (from-to)753-764
Number of pages12
JournalMolecular pharmacology
Volume96
Issue number6
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Single-Domain Antibodies
Chemokine Receptors
G-Protein-Coupled Receptors
Monoclonal Antibodies
Immunoglobulin Fragments
Antibodies
Public Opinion
Therapeutics
Chemokines
Research
Autoimmune Diseases
Neoplasms
Pharmaceutical Preparations

Cite this

@article{9bd9fa76c798421a827f951c13df3a6e,
title = "Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3",
abstract = "Dysregulation of the chemokine system is implicated in a number of autoimmune and inflammatory diseases, as well as cancer. Modulation of chemokine receptor function is a very promising approach for therapeutic intervention. Despite interest from academic groups and pharmaceutical companies, there are currently few approved medicines targeting chemokine receptors. Monoclonal antibodies (mAbs) and antibody-based molecules have been successfully applied in the clinical therapy of cancer and represent a potential new class of therapeutics targeting chemokine receptors belonging to the class of G protein-coupled receptors (GPCRs). Besides conventional mAbs, single-domain antibodies and antibody scaffolds are also gaining attention as promising therapeutics. In this review, we provide an extensive overview of mAbs, single-domain antibodies, and other antibody fragments targeting CXCR4 and ACKR3, formerly referred to as CXCR7. We discuss their unique properties and advantages over small-molecule compounds, and also refer to the molecules in preclinical and clinical development. We focus on single-domain antibodies and scaffolds and their utilization in GPCR research. Additionally, structural analysis of antibody binding to CXCR4 is discussed. SIGNIFICANCE STATEMENT: Modulating the function of GPCRs, and particularly chemokine receptors, draws high interest. A comprehensive review is provided for monoclonal antibodies, antibody fragments, and variants directed at CXCR4 and ACKR3. Their advantageous functional properties, versatile applications as research tools, and use in the clinic are discussed.",
author = "Vladimir Bobkov and Marta Arimont and Aur{\'e}lien Zarca and {De Groof}, {Timo W.M.} and {van der Woning}, Bas and {de Haard}, Hans and Smit, {Martine J.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1124/mol.119.116954",
language = "English",
volume = "96",
pages = "753--764",
journal = "Molecular pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3. / Bobkov, Vladimir; Arimont, Marta; Zarca, Aurélien; De Groof, Timo W.M.; van der Woning, Bas; de Haard, Hans; Smit, Martine J.

In: Molecular pharmacology, Vol. 96, No. 6, 01.12.2019, p. 753-764.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3

AU - Bobkov, Vladimir

AU - Arimont, Marta

AU - Zarca, Aurélien

AU - De Groof, Timo W.M.

AU - van der Woning, Bas

AU - de Haard, Hans

AU - Smit, Martine J.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Dysregulation of the chemokine system is implicated in a number of autoimmune and inflammatory diseases, as well as cancer. Modulation of chemokine receptor function is a very promising approach for therapeutic intervention. Despite interest from academic groups and pharmaceutical companies, there are currently few approved medicines targeting chemokine receptors. Monoclonal antibodies (mAbs) and antibody-based molecules have been successfully applied in the clinical therapy of cancer and represent a potential new class of therapeutics targeting chemokine receptors belonging to the class of G protein-coupled receptors (GPCRs). Besides conventional mAbs, single-domain antibodies and antibody scaffolds are also gaining attention as promising therapeutics. In this review, we provide an extensive overview of mAbs, single-domain antibodies, and other antibody fragments targeting CXCR4 and ACKR3, formerly referred to as CXCR7. We discuss their unique properties and advantages over small-molecule compounds, and also refer to the molecules in preclinical and clinical development. We focus on single-domain antibodies and scaffolds and their utilization in GPCR research. Additionally, structural analysis of antibody binding to CXCR4 is discussed. SIGNIFICANCE STATEMENT: Modulating the function of GPCRs, and particularly chemokine receptors, draws high interest. A comprehensive review is provided for monoclonal antibodies, antibody fragments, and variants directed at CXCR4 and ACKR3. Their advantageous functional properties, versatile applications as research tools, and use in the clinic are discussed.

AB - Dysregulation of the chemokine system is implicated in a number of autoimmune and inflammatory diseases, as well as cancer. Modulation of chemokine receptor function is a very promising approach for therapeutic intervention. Despite interest from academic groups and pharmaceutical companies, there are currently few approved medicines targeting chemokine receptors. Monoclonal antibodies (mAbs) and antibody-based molecules have been successfully applied in the clinical therapy of cancer and represent a potential new class of therapeutics targeting chemokine receptors belonging to the class of G protein-coupled receptors (GPCRs). Besides conventional mAbs, single-domain antibodies and antibody scaffolds are also gaining attention as promising therapeutics. In this review, we provide an extensive overview of mAbs, single-domain antibodies, and other antibody fragments targeting CXCR4 and ACKR3, formerly referred to as CXCR7. We discuss their unique properties and advantages over small-molecule compounds, and also refer to the molecules in preclinical and clinical development. We focus on single-domain antibodies and scaffolds and their utilization in GPCR research. Additionally, structural analysis of antibody binding to CXCR4 is discussed. SIGNIFICANCE STATEMENT: Modulating the function of GPCRs, and particularly chemokine receptors, draws high interest. A comprehensive review is provided for monoclonal antibodies, antibody fragments, and variants directed at CXCR4 and ACKR3. Their advantageous functional properties, versatile applications as research tools, and use in the clinic are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85075088815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075088815&partnerID=8YFLogxK

U2 - 10.1124/mol.119.116954

DO - 10.1124/mol.119.116954

M3 - Article

VL - 96

SP - 753

EP - 764

JO - Molecular pharmacology

JF - Molecular pharmacology

SN - 0026-895X

IS - 6

ER -